Drug Approval | October 21, 2025
FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Dupixent peak sales ambition raised to more than €13 billion
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Subscribe To Our Newsletter & Stay Updated
